Femasys (NASDAQ:FEMY – Get Free Report) and Solventum (NYSE:SOLV – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, profitability, earnings and analyst recommendations.
Profitability
This table compares Femasys and Solventum’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Femasys | -534.36% | -225.97% | -74.68% |
| Solventum | 17.26% | 25.09% | 8.78% |
Earnings and Valuation
This table compares Femasys and Solventum”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Femasys | $2.29 million | 9.81 | -$18.63 million | ($3.53) | -0.76 |
| Solventum | $8.32 billion | 1.84 | $1.56 billion | $8.18 | 11.03 |
Solventum has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Femasys and Solventum, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Femasys | 1 | 0 | 3 | 0 | 2.50 |
| Solventum | 1 | 4 | 8 | 0 | 2.54 |
Femasys currently has a consensus target price of $50.00, indicating a potential upside of 1,765.67%. Solventum has a consensus target price of $91.64, indicating a potential upside of 1.58%. Given Femasys’ higher probable upside, analysts plainly believe Femasys is more favorable than Solventum.
Volatility and Risk
Femasys has a beta of -2.07, meaning that its share price is 307% less volatile than the S&P 500. Comparatively, Solventum has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Institutional and Insider Ownership
65.3% of Femasys shares are owned by institutional investors. 7.7% of Femasys shares are owned by company insiders. Comparatively, 0.2% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Solventum beats Femasys on 10 of the 14 factors compared between the two stocks.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.
Receive News & Ratings for Femasys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Femasys and related companies with MarketBeat.com's FREE daily email newsletter.
